Clinical trial · Interventional
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial
NCT05300958CI-TRIAL-00092460terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficulty accruing subjects the study accrual was closed.
Summary
Brief summary (as posted)
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Deferoxamine Plus Chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment arm
- description
- Deferoxamine：50mg/kg+500ml normal saline (NS) plus chemotherapy
- interventionNames
- Drug: Deferoxamine Plus Chemotherapy
Primary outcomes (1)
- measure
- Objective Response Rate (ORR)
- timeFrame
- 6 months
- description
- the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period
Secondary outcomes (3)
- measure
- clinical benefit rate (CBR)
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria. * Fail second-line or above anti-tumor treatment * Evaluation is stable disease with a trend of progression. * Minimum life expectancy 16 weeks * Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis * ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks * Normal organ function. * Has signed a Patient Informed Consent Form. Exclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) score of ≥ 2 * Patients with severe liver and kidney insufficiency * Deferoxamine Ingredients allergy * With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment * Inability or unwillingness to comply with study procedures, including inability to take regular oral medication * Researchers consider it is not suitable for participation.
References
Publications (0)
Data not yet available
No reference posted for this study.